159 related articles for article (PubMed ID: 37869012)
1. Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.
Gao H; Chang RZ; Chen XP; Zhang WG; Zhang B; Luo X; Ding ZY
Front Immunol; 2023; 14():1274449. PubMed ID: 37869012
[TBL] [Abstract][Full Text] [Related]
2. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
6. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.
Nikoo M; Hassan ZF; Mardasi M; Rostamnezhad E; Roozbahani F; Rahimi S; Mohammadi J
Pathol Res Pract; 2023 Jul; 247():154473. PubMed ID: 37207558
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
11. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
12. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
Moreno-Cubero E; Larrubia JR
World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
14. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
15. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
16. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.
Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M
Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
20. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
